Sign in
Taking peopleNo phase

Testing heart mapping to guide pacemaker lead placement in heart failure

Tests whether heart mapping guides cardiac resynchronization device placement in adults with heart failure.

Key facts

Who runs it
EP Solutions SA
Where
London and Oxford, United KingdomSee the 3 sitesAlso in 3 other countries, 8 sites
Trial code
Registry title
Improving CRT Outcome With Non-Invasive Cardiac Mapping
Status
Recruiting
People taking part
330 people, planned
Started
20 Dec 2023
Expected to end
Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Pre-implantation planning
  • Post-implantation assessment
Record updated
7 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with heart failure with reduced ejection fraction who are about to get a CRT device with biventricular pacing. It tests whether a heart map helps place the left ventricular lead.

Age
18 to 85 years
Sex
All sexes
Disease stage
Heart failure in sinus rhythm that meets Class I or IIa criteria of the 2013 ESC CRT guidelines. A CRT device with biventricular (BiV) pacing is planned.
Earlier treatment
Must have had optimal medical therapy for heart failure for at least 3 months before screening. Must not have had a pacemaker, CRT or ICD implanted before.

Main reasons for not taking part

  • Previous pacemaker, CRT or ICD implant
  • Acute disease or flare of a long-term disease, as the investigator decides
  • Cannot have a CT scan
  • Cannot have body surface ECG mapping (for example a healing chest wound, skin disease, or allergy to the electrodes or band-aid)
  • Pregnant, or planning pregnancy within 6 months after signing consent

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Appropriately signed and dated informed consent
  • Age ≥18 years at time of consent
  • Received optimal medical therapy for HF for at least 3 months before screening
  • Patient in sinus rhythm at the time of screening fulfilling Class I or IIa criteria per ESC CRT guidelines 2013
  • Patient is intended for placement of a CRT device with biventricular (BiV) pacing

Who cannot take part

  • Previous cardiac pacemaker/CRT/ICD implantation
  • Acute diseases or exacerbations of chronic diseases (as per the investigator's discretion)
  • Contraindications to body surface ECG mapping: (ongoing wound healing on the chest (e.g. recent surgery), skin diseases, allergic reactions to surface mapping electrodes and medical band-aid)
  • Pregnant, or subjects planning to become pregnant within 6 months after signing informed consent (a documented negative pregnancy test (serum or blood) is required for women of childbearing potential)
  • Contraindications to CT scanning
  • Incapacitated individuals, defined as persons who are mentally ill, mentally handicapped, or individuals without legal authority, are excluded from the study population

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

Where in United Kingdom

Also in 3 other countries, 8 sites

  • Bart's HospitalLondon, United KingdomContact: Pier Lambiase, DrNot yet recruiting
  • King's CollegeLondon, United KingdomContact: Aldo Rinaldi, DrNot yet recruiting
  • Oxford University HospitalOxford, United KingdomContact: Tim Betts, DrNot yet recruiting

About the trial

What the trial wants to find out

The ICONIC-M study is a multicenter randomized controlled study to assess patient response to CRT comparing ECGI map guided left ventricular lead placement with empirical lead placement.

Read full original descriptionShow less

The hypothesis of the investigation is to demonstrate that CRT LV lead implantation guided by a map obtained with the Amycard 01C System and showing LV Latest Electrical Activated Site (LEAS) in combination with a CT cardiac venogram improves CRT outcome. An improved CRT outcome is defined as a ≥30% increase in LVESVi reduction compared to empiric CRT LV lead implantation.

The sample size will be 136 in the Control arm and 194 in the Active arm. A total of 330 subjects.

The study follows an adaptive design, in where one interim analysis at 70% enrollment will be performed. The sponsor may stop enrollment when either one of the following conditions apply:

* Statistical significant difference between groups in the primary endpoint has been reached confirming a difference in reduction of the LVESVi of ≥30% in the Active arm compared to the Control arm * There is no trend or reason to believe statistical significance will be reached with a higher sample size.

Statistical significance (primary endpoint) is reached at interim (70%) or at total (100%) of enrollment with a significance value P lower than 0.025.

The 2 groups in the trial

  • ControlExisting treatment, for comparison

    The CRT device is implanted according to clinical practice, without pre-implantation planning. The outcome of the procedure is assessed via echography as per clinical practice. In addition to clinical practice, the subjects are required to fill in a quality-of-life questionnaire and are subject to an ECG mapping procedure with the Amycard 01C device, including non-contrast CT, to assess the distance between left ventricular lead placement and the latest electrical activation site in the absence of planning information.

    Treatment: Post-implantation assessment

  • ActiveTreatment being tested

    A pre-implantation ECG mapping with the Amycard 01C device, including CT, is performed prior to the CRT device implantation. The resulting target area for the left ventricular lead placement is communicated to the implanting physician, who will attempt to reach a point close to the target, using the available venous access. At six-month follow-up, response to the therapy is assessed using echocardiography, and a second ECG mapping with Amycard 01C is performed, to assess the distance between actual implantation site and target in the presence of pre-implantation planning information.

    Treatment: Pre-implantation planning and Post-implantation assessment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
ICONIC-M: Improving CRT Outcome With Non-Invasive Cardiac Mapping. A Multicenter Randomized Controlled Study To Assess Patient Response to CRT Comparing ECGI Map Guided Left Ventricular Lead Placement With Empirical Lead Placement
Plain-language title
Testing heart mapping to guide pacemaker lead placement in heart failureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05564793, who can take part
Record updated
7 August 2025